Heterologous Expression of the Unusual Terreazepine Biosynthetic Gene Cluster Reveals a Promising Approach for Identifying New Chemical Scaffolds

Lindsay K. Caesar,a Matthew T. Robey,b Michael Swyers,c Md N. Islam,c Rosa Ye,c Purav P. Vagadia,d Gary E. Schiltz,d,e,f Paul M. Thomas,h,g Cheng C. Wu,c Neil L. Kelleher,a,b,g Nancy P. Keller,h,i Jin Woo Bokh

aDepartment of Chemistry, Northwestern University, Evanston, Illinois, USA
bDepartment of Molecular Biosciences, Northwestern University, Evanston, Illinois, USA
cIntact Genomics, Inc., St. Louis, Missouri, USA
dCenter for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois, USA
eDepartment of Pharmacology, Northwestern University, Chicago, Illinois, USA
fRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
gProteomics Center of Excellence, Northwestern University, Chicago, Illinois, USA
hDepartment of Medical Microbiology and Immunology, University of Wisconsin—Madison, Madison, Wisconsin, USA
iDepartment of Bacteriology, University of Wisconsin—Madison, Madison, Wisconsin, USA

Lindsay K. Caesar and Matthew T. Robey contributed equally to this work. Lindsay K. Caesar did the majority of the writing of this article, so she was chosen to be listed first.

ABSTRACT Advances in genome sequencing have revitalized natural product discovery efforts, revealing the untapped biosynthetic potential of fungi. While the volume of genomic data continues to expand, discovery efforts are slowed due to the time-consuming nature of experiments required to characterize new molecules. To direct efforts toward uncharacterized biosynthetic gene clusters most likely to encode novel chemical scaffolds, we took advantage of comparative metabolomics and heterologous gene expression using fungal artificial chromosomes (FACs). By linking mass spectral profiles with structural clues provided by FAC-encoded gene clusters, we targeted a compound originating from an unusual gene cluster containing an indoleamine 2,3-dioxygenase (IDO). With this approach, we isolate and characterize R and S forms of the new molecule terreazepine, which contains a novel chemical scaffold resulting from cyclization of the IDO-supplied kynurenine. The discovery of terreazepine illustrates that FAC-based approaches targeting unusual biosynthetic machinery provide a promising avenue forward for targeted discovery of novel scaffolds and their biosynthetic enzymes, and it also represents another example of a biosynthetic gene cluster “repurposing” a primary metabolic enzyme to diversify its secondary metabolite arsenal.

IMPORTANCE Here, we provide evidence that Aspergillus terreus encodes a biosynthetic gene cluster containing a repurposed indoleamine 2,3-dioxygenase (IDO) dedicated to secondary metabolite synthesis. The discovery of this neofunctionalized IDO not only enabled discovery of a new compound with an unusual chemical scaffold but also provided insight into the numerous strategies fungi employ for diversifying and protecting themselves against secondary metabolites. The observations in this study set the stage for further in-depth studies into the function of duplicated IDOs present in fungal biosynthetic gene clusters and presents a strategy for accessing the biosynthetic potential of gene clusters containing duplicated primary metabolic genes.

KEYWORDS IDO, heterologous expression, natural products, Aspergillus terreus, Aspergillus nidulans, genome mining, Aspergillus, biosynthetic gene cluster, indoleamine 2,3-dioxygenase, kynurenine, NRPS

Citation Caesar LK, Robey MT, Swyers M, Islam MN, Ye R, Vagadia PP, Schiltz GE, Thomas PM, Wu CC, Kelleher NL, Keller NP, Bok JW. 2020. Heterologous expression of the unusual terreazepine biosynthetic gene cluster reveals a promising approach for identifying new chemical scaffolds. mBio 11:e01691-20. https://doi.org/10.1128/mBio.01691-20.

Editor Julian E. Davies, University of British Columbia
Copyright © 2020 Caesar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Cheng C. Wu, cwu@intactgenomics.com, Neil L. Kelleher, n-kelleher@northwestern.edu, Nancy P. Keller, npkeller@wisc.edu, or Jin Woo Bok, jbob@wisc.edu.
This article is a direct contribution from Nancy P. Keller, a Fellow of the American Academy of Microbiology, who arranged for and secured reviews by B. Tungeon, Cornell University; and Yit Heng Chooi, The University of Western Australia.
Received 13 July 2020
Accepted 21 July 2020
Published 25 August 2020
Fungal natural products (secondary metabolites) are an invaluable source of inspiration for pharmaceuticals that act against myriad conditions, including infectious diseases, cancer, and hyperlipidemia (1–4). Indeed, the antibiotics penicillin and cephalosporin, the cholesterol-lowering lovastatin, and the immunosuppressant cyclosporine are derived from fungi (5, 6), and the reservoir of novel scaffolds continues to grow each year (7). Although numerous drugs derived from fungi exist on the market today, genome sequencing has revealed that fungi possess the biosynthetic capacity to produce a far greater number of secondary metabolites than currently accessed (8).

Recent studies spanning nearly 600 fungal genomes suggest that a mere 3% of molecules encoded by fungal biosynthetic gene clusters (BGCs) have been explored (8). To access this biosynthetic potential, an innovative discovery pipeline was recently developed to systematically annotate the biosynthetic abilities of fungi using comparative metabolomics and heterologous gene expression (9–12). With this platform, fungal genomic DNA fragments containing intact BGCs are inserted into fungal artificial chromosomes (FACs) and are used to transform a fungal host to discover new chemical scaffolds (10–12). This pipeline uses a metabolite scoring system to identify heterologously expressed metabolites from the thousands of signals originating from the host. By enabling facile linkage between secondary metabolites and their corresponding BGCs, the FAC-metabolite scoring pipeline facilitates prioritization of target compounds most likely to contain novel scaffolds.

Aromatic amino acids are fundamental for growth and development across phylogenetic kingdoms. Additionally, catabolism of aromatic amino acids leads to the production of nonproteinogenic amino acids, such as the tryptophan-derived kynurenine, which regulates inflammation and immune responses (13, 14). Kynurenine and its derivatives are biosynthetic intermediates of numerous secondary metabolites, including sibiromycin (15), mycemyclin C (16), nidulanin A (17), nidulanin B and nidulanin D (18), daptomycin (19), and quinomycin peptide antibiotics (20). Recently, the malpikynines were discovered from Mortierella alpina as degradation products of the fungal surfactant malpinins, resulting from an oxidative conversion of tryptophan into kynurenine (21). Incorporation of kynurenine into secondary metabolites enables differential specificity toward enzyme receptors and targets (22). Daptomycin, for example, shows decreased antimicrobial efficacy when kynurenine is mutated to tryptophan (23, 24). One tactic for creating secondary metabolites with novel scaffolds is to recruit primary metabolic enzymes that modify common precursors into nonproteinogenic precursors into BGCs (20). For example, a tryptophan 2,3-dioxygenase (TDO) gene located adjacent to the daptomycin-producing nonribosomal peptide synthetase (NRPS) gene encodes an enzyme that supplies the kynurenine for daptomycin synthesis. This TDO diverges from related proteins in the same genus (29% sequence identity), suggesting it is a paralogous enzyme dedicated to secondary metabolite biosynthesis (19).

In a large-scale analysis of 56 FACs, an unknown metabolite from heterologous expression of a BGC from Aspergillus terreus ATCC 20542 (located on the FAC AtFAC7O19; Fig. 2A; also see Table S1 in the supplemental material) was identified with an m/z value of 310.1188 and a molecular formula of C_{17}H_{15}N_{3}O_{3} (calculated [M+H]^{+} mass 310.1192, −0.97 ppm) (10). This compound was found in both the parent strain and the AtFAC7O19-transformed Aspergillus nidulans, but not in the empty vector control. Interestingly, the BGC encoding this metabolite contained an indoleamine 2,3-dioxygenase (IDO), which is involved in tryptophan degradation via kynurenine production (25). While most aspergilli contain three IDOs, A. terreus contains four (see Fig. S1 in the supplemental material). Given that gene duplication is often utilized as a strategy to "repurpose" genes for secondary metabolism, the presence of this fourth IDO suggested that it may serve to supply kynurenine for the formation of the unknown metabolite. Here, we employ the FAC-metabolite scoring strategy to identify the biosynthetic product of this unusual gene cluster and probe its biosynthesis.
RESULTS

To determine the structure of the target compound, ~1.5 mg of material was purified from FAC-transformed *A. nidulans* extracts and subjected to tandem mass spectrometry (MS²) analysis, ¹H and ¹³C nuclear magnetic resonance (NMR) spectroscopy, and two-dimensional (2D) correlation approaches, including correlation spectroscopy (COSY), heteronuclear single quantum correlation (HSQC), and heteronuclear multiple bond correlation (HMBC) (see Table S2 and Fig. S2 and S3 in the supplemental material). Structural analysis revealed an unusual secondary metabolite backbone, a 3,4-dihydro-¹H-1-benzazepine-2,5-dione, resulting from the unusual cyclization of kynurenine. The metabolite’s structure matches that of a previously synthesized kynurenine derivative, 2-amino-Ν-(2,3,4,5-tetrahydro-2,5-dioxo-1H-1-benzazepin-3-yl) benzamide (26). On the basis of its structure and the parent organism, it was given a common name of “terreazepine.” To determine the stereochemical configuration of terreazepine, R and S enantiomers were synthesized, each with an enantiomeric excess of ≥95% (Fig. S4). Each enantiomer and the purified natural compound were acylated to enable separation using supercritical fluid chromatography. Interestingly, natural terreazepine was found to be a 2:1 mixture of S-R enantiomers by comparing against synthetic standards separated by chiral chromatography (Fig. S4). During the course of this work, Li et al. reported the independent discovery of (S)-terreazepine (nanangele-nin B) as an intermediate in the biosynthesis of the related compound nanangelenin A (27). Given that our discovery of terreazepine was completed prior to the publication by Li et al., the strategies outlined herein nonetheless provide promise for the discovery of novel chemical scaffolds.

To probe terreazepine’s biosynthesis, we grew *A. terreus* (ATCC 20542) using media containing isotopically labeled biosynthetic precursors. Labeling with [¹³C₆]anthranilate resulted in an m/z shift of +6 Da (Fig. 2B), supporting incorporation of anthranilate into the molecule (Fig. 2C). Consistent with terreazepine’s chemical structure, labeling with l-Trp-D₅ did not result in the expected shift of +5 in the mass spectrum, instead resulting in a mass shift of +4 (Fig. 2B). Given the existence of an IDO in the AtFAC7019 BGC, these data provide support that tryptophan is converted into kynurenine prior to incorporation into terreazepine. For further confirmation of the IDO activity in terreazepine biosynthesis, a FAC deletion mutant was produced lacking the IDO *tzpB* by RedET-mediated recombineering (10). Mass spectral analysis of the FAC deletion mutant revealed no terreazepine production (Fig. S5).

Homology-based annotation of the FAC-encoded NRPS revealed a domain structure consisting of two adenylation (A), two condensation (C), and three thiolation (T)
domains, giving the domain sequence A1-T1-C1-A2-T2-C2-T3. To investigate the function of the seemingly extraneous T3 domain, we constructed FAC truncation mutants either lacking the C2T3 domains (ΔC2T3) or only the T3 domain (ΔT3). These constructs were transformed into *A. nidulans*, and extracted metabolites were subjected to liquid chromatography-mass spectrometry (LC-MS) analysis. A very small amount of the target compound was detected in ΔC2T3 extracts (5,000-fold lower than control), suggesting that terreazepine formation can occur slowly without catalysis. We were unable to detect the presence of any offloaded intermediates. Interestingly, ΔT3 extracts contained terreazepine levels close to that of the intact NRPS (Fig. 2D). Given that analyses focused on endpoint abundance of terreazepine, it is possible that the T3 domain increases the catalytic efficiency of product formation. This is in contrast to recent findings by Li et al. in which NanA, the TzpA ortholog involved in nanangelenin A biosynthesis, requires the T3 domain for product formation (27). The reasons for these differences are unknown but may involve differences in protein sequence or other ancillary protein interactions.

**FIG 2** Proposed terreazepine biosynthetic pathway. (A) The terreazepine biosynthetic gene cluster. (B) Mass spectral shifts of terreazepine following feeding with l-tryptophan-D5 and [13C6]anthranilate. (C) Proposed incorporation of isotope-labeled precursors into terreazepine. (D) Selected ion chromatograms of terreazepine in tzpA domain deletion mutants. (E) Proposed NRPS assembly of terreazepine. It remains unclear whether the final cyclization event can occur from both T2 and T3 domains.
Using heterologous expression, stable isotope feeding studies, and NRPS backbone deletions, we propose a biosynthetic scheme for terreazepine (Fig. 2E). In this scheme, N-formyl-kynurenine is formed through the catabolism of tryptophan by TzpB, an IDO. TzpB shares 41% sequence identity to *Aspergillus fumigatus* IdOA and 45% identity to IdOB, and only 26% identity to IdOC. Enzymatic studies using *Aspergillus oryzae* suggest that only idoa and idob (orthologs of idoa and idob, respectively) encode enzymes that participate in tryptophan catabolism (28, 29). Because most aspergilli contain three IDOs, TzpB, a fourth IDO in the parent organism *A. terreus*, may no longer play a role in primary metabolism and instead represent a duplicated enzyme dedicated to terreazepine biosynthesis (Fig. S1). This is reminiscent of daptomycin biosynthesis in *Streptomyces roseosporus*, in which the TDO DptJ supplies kynurenine for daptomycin formation (19). The biosynthesis of terreazepine mirrors that of its relative nanangelenin A, where tzpA and tzpB orthologs in *Aspergillus nanangensis* (nanA and nanC) encode enzymes with near identical activity.

As the next step in the proposed biosynthesis, TzpA, a two-module NRPS, utilizes anthranilate and kynurenine to assemble terreazepine. The first adenylation domain (TzpA-A1) loads anthranilate onto the T1 domain, while TzpA-A2 loads kynurenine, generated through spontaneous nonenzymatic deformylation of the TzpB-supplied N-formyl-kynurenine. The substrate-binding residues of TzpA-A1 resemble those of other fungal adenylation domains that recognize anthranilate (Table S3). TzpA-A2, responsible for incorporating kynurenine, has a new pocket code quite dissimilar from other kynurenine-binding A-domains (Table S3). However, this disparity may be attributable to evolutionary distance between source organisms and the unstudied nature of kynurenine incorporation into fungal secondary metabolites. Given that the isolated terreazepine was a 2:1 mixture of S-R enantiomers, we can speculate that TzpA-A2 accepts both D- and L-kynurenine. The peptide bond formation between the tethered amino acids is catalyzed by the first condensation domain, TzpA-C1, between anthranilate’s carbonyl carbon and kynurenine’s aliphatic primary amine. The second C domain (TzpA-C2) catalyzes the final cyclization event between the aromatic amine of kynurenine and the tethered carbonyl carbon, yielding the final terreazepine product.

While the role of the terminal TzpA-T3 domain remains uncertain, we can glean insight by looking at related NRPSs. For example, the unusual NRPS domain structure of TzpA mirrors that of GlIP, the NRPS involved in gliotoxin biosynthesis (30, 31). When studied in vitro, GlIP mutants show behavior mirroring that of TzpA deletants: truncated GlIP ΔT3 mutants retain dipeptide synthetase activity, while ΔC2T3 mutants show reduced activity (30, 31). However, in vivo, GlIP ΔT3 loses activity, suggesting that the in vivo pathway involves transfer of the dipeptidyl-S intermediate from T2 to T3 (30). In light of these two possible pathways of cyclization from T2 and T3, as well as a slow reported rate of approximately 1 per h, it has been suggested that T3 facilitates interaction with downstream tailoring enzymes (30, 31). Given that terreazepine biosynthesis does not appear to require the activity of downstream tailoring enzymes, both cyclization pathways may exist. Like the T domains of GlIP, TzpA-T2 and T3 possess the predicted active site residue (S1937 and S2473, respectively), suggesting that they are both functional (Table S3). Similarly, TzpA-C2 possesses the purported catalytic histidine at position H2137. However, the adjacent residue sequence diverges from the conserved SHXXXXDXX(S/T) sequence shared by diketopiperazine-forming NRPSs such as GlIP and HasD (30), and slightly from the SHXXXX sequence of NanA (27), suggesting it may have different cyclization requirements (Table S3). More studies will be required to elucidate the nuanced functions of terminal T domains in natural product biosynthesis.

The discovery of terreazepine and its BGC revealed that fungal IDOs can play a role in secondary metabolite biosynthesis and that kynurenine incorporation into secondary metabolites can yield novel chemical scaffolds. This suggests that targeted efforts to characterize fungal BGCs containing IDOs may facilitate the discovery of completely new molecules with unique chemical scaffolds and their derivatives. To explore this...
possibility, we searched sequences of 1,037 fungal genomes from GenBank and the Joint Genome Institute and located BGCs containing IDOs. Of the ∼38,000 BGCs contained within these genomes, 118 contain an IDO. We then grouped IDO-containing BGCs into gene cluster families (GCFs) based on sequence identity and the fraction of protein domains shared between BGC pairs, anticipating that a single GCF groups BGCs that produce similar metabolites. Of the 118 IDO-containing BGCs, 68 were sorted into 16 GCFs. The remaining 50 BGCs represent singletons that had no similar BGC pairs (Fig. 3A).

Several interesting insights can be gleaned from this analysis. First, many BGCs originate from phylogenetically diverse aspergilli, an NRPS-containing subset of which are illustrated in Fig. 3B. BGCs from two *Aspergillus* GCFs in particular were identified as putative terreazepine clusters. The first GCF includes the terreazepine BGC itself, which exists in *Aspergillus terreus* and *A. pseudotereus*. The second GCF contains BGCs from *Aspergillus thermomutatus*, *A. funiculosus*, and *A. lentulus*. The NRPSs in this GCF follow the same unusual domain sequence of ATCATCT (with the exception of *A. lentulus* which lacks the terminal T domain). Adenylation domain specificity codes bear remarkable similarity to those of TzpA-A₁ and TzpA-A₂ (Table S3), suggesting that these NRPSs biosynthesize terreazepine. Unlike the terreazepine BGC, however, the BGCs in this family contain several tailoring enzymes expected to diversify the terreazepine scaffold, raising the possibility that the shared NRPS T₃ facilitates interaction with downstream enzymes in these pathways.

The tailoring enzymes present in these BGCs differ from those present in the nanangelenin A cluster in *A. nanangensis*, indicating that a variety of terreazepine/nanangelenin analogs may exist (27). Moreover, IDO-containing BGCs from *Aspergillus ibericus* and *A. homomorphus* may encode yet undiscovered dipeptide scaffolds containing kynurenine (Fig. 3B). Interestingly, the IDOs contained in these three GCFs represent a distinct clade of duplicated IDOs with moderate sequence homology (∼40%) to both *A. fumigatus* IdoA and IdoB (Fig. S1).

Perhaps even more remarkable is the degree to which IDO-containing BGCs span the kingdom of fungi, encompassing five taxonomic classes and two phyla (Fig. S6). Particularly interesting is the presence of several NRPS-containing BGCs originating from Basidiomycetes, given the rare and unstudied nature of NRPSs in this phylum (32). Taken together, these results reveal the rich biosynthetic potential of IDO-containing BGCs that has only just begun to be explored.

**DISCUSSION**

The work described herein has elucidated a clear biosynthetic role for two FAC-encoded enzymes, TzpA, an NRPS, and TzpB, an IDO, in the biosynthesis of terreazepine. A closer look at the genes surrounding *tzpA* and *tzpB*, however, reveals additional genes that could play a role in biosynthesis. Indeed, adjacent genes include an alcohol dehydrogenase (*ATEG_07354*), a transcription factor (*ATEG_07357*), and a P450 (*ATEG_07362*) (Fig. 2A; see Table S1 in the supplemental material). While we were unable to determine whether these additional genes encode regulatory elements or biosynthetic players involved in terreazepine formation, a few possibilities warrant discussion.

First, it is possible that the tailoring enzymes present in the gene cluster (i.e., the P450 and the alcohol dehydrogenase) remain silent and that the gene cluster itself is only partially expressed. Given that only (S)-terreazepine is formed as an intermediate in nanangelenin A production in *A. nanangensis* (27), a second possibility is that these tailoring enzymes play a role in the epimerization of (S)-terreazpine to (R)-terreazepine. This epimerization could occur through a two-step mechanism similar to that of the conversion of (S)-reticuline to (R)-reticuline in *Saccharomyces cerevisiae* (33). Should this be the case, it would follow that TzpA produces (S)-terreazepine which is then oxidized from an amine to an enamine by the P450. This oxidized product could then be reduced by the alcohol dehydrogenase/oxidoreductase to form the S-R mixture that we observed. Of course, the activities of these enzymes are at this point only speculative,
and future studies will be required to confirm what, if any, roles these enzymes play in terreazepine biosynthesis.

The discovery of terreazepine provides another example of how fungi repurpose primary metabolism genes for secondary metabolism. On the basis of this and other
examples, we propose two major strategies fungi employ for such repurposing: type I repurposing into biosynthetic enzymes and type II repurposing into resistance genes (Fig. 4). One of the earliest discoveries of type I repurposing is that of the important fungal toxin sterigmatocystin. Evaluation of the sterigmatocystin biosynthetic pathway revealed the presence of two fatty acid synthase (FAS) genes, \textit{stcJ} and \textit{stcK} located within the sterigmatocystin gene cluster. Indeed, disruption of these genes in \textit{A. nidulans} resulted in strains that did not produce sterigmatocystin but were morphologically identical to wild-type strains (34). Another important example of type I repurposing is the duplicated isopropyl-malate synthase (IPMS) involved in echinocandin biosynthesis in \textit{Emericella rugulosa}. Similar to the provision of kynurenine by TzpB, this duplicated IPMS serves to provide the nonproteinogenic amino acid homotyrosine for incorporation into echinocandin B (Fig. 4) (35).

In addition to repurposing duplicated primary metabolism genes to have a biosynthetic role, fungi also utilize duplicated genes from primary metabolism as a form of self-resistance (36, 37). This type II repurposing represents a particularly attractive avenue for drug discovery, as the duplicated gene will often provide insight into the mechanism of action of the encoded secondary metabolite. Several examples of such type II repurposing have been discovered by targeting clusters with duplicate resistance targets. The proteasome inhibitor fellutamide B, for example, was discovered due to the presence of a duplicated proteasome subunit within its BGC (38). Similarly, the BGC encoding the methionine aminopeptidase inhibitor fumagillin contains both type I and type II methionine aminopeptidase genes in the gene cluster (Fig. 4) (39). While it is likely that many of the IDOs contained within the BGCs depicted in Fig. 3 and Fig. 5 represent type I biosynthetic enzymes that provide kynurenine for secondary metabolite synthesis, it is also possible that they represent type II duplicated gene targets that serve to protect the producing organism against the biosynthetic product. Indeed, when we began this research, we suspected that terreazepine might possess IDO inhibitory activity and show promise as an anticancer agent (40). When tested against \textit{A. fumigatus} IDO mutants, however, no growth inhibitory activity was observed (data not shown). Future studies aimed to elucidate the biosynthetic products of additional IDO-containing BGCs in fungi offer exciting opportunities not only to discover new molecular scaffolds but also to identify anticancer metabolites with known mechanisms of action.
In sum, this work has shown the feasibility of using FACs to discover secondary metabolites from unusual BGCs. With this approach, we identified, reconstructed, and heterologously expressed an unusual BGC encoding the novel metabolite terreazepine. Thus far, IDO involvement in secondary metabolite biosynthesis in fungi has only just begun to be explored, suggesting that future efforts targeting BGCs including IDOs and other unusual biosynthetic players may prove fruitful. By mapping BGC relatedness across the fungal kingdom, we also uncover evidence of numerous IDO-containing BGCs in phylogenetically diverse fungi that may encode metabolites with novel chemical scaffolds or IDO inhibitory activity. This approach shows promise for focusing natural product discovery efforts toward uncharted biosynthetic space, yielding a diverse array of novel molecular scaffolds.

MATERIALS AND METHODS

FAC Generation, transformation, growth, and extraction. AtFAC7019 was produced in a prior study through the unbiased random shear of Aspergillus terreus ATCC 20542 genomic DNA (10). Using previously described methods, targeted metabolomics and FAC metabolite scoring identified a target compound with m/z 310,1188 that was likely to be produced from this FAC (10). AtFAC7019 was then maintained in Escherichia coli strain DH10B and used to transform the Red/ET-inducible E. coli strain SW012 prior to DNA preparation and transformation of A. nidulans, as described in a previous study (11). Following transformation of A. nidulans, growth and extraction of FAC-containing and control strains were completed as previously reported (10).

LC-MS analysis. Dried metabolite extracts were resuspended in methanol to a concentration of 10 mg/mL. Samples were sonicated for 10 min and then centrifuged for 10 min at 21,000 × g. Samples were analyzed by LC-MS using a Thermo Q Exactive mass spectrometer with an inline Agilent 1290 ultra-high performance liquid chromatograph (UHPLC) with a Phenomenex Kinetex 1.3-µm-particle-size column with dimensions 2 × 100 mm. Five percent acetonitrile in water with 0.01% formic acid was used as buffer A, and 100% acetonitrile with 0.1% formic acid was used as buffer B. An 8 min, 0 to 100% buffer B, gradient was used. The MS heated electrospray ionization (HESI) source was set at 275°C, with sheath gas set at 60 arbitrary units and spray voltage set at 3.5 kV. Data were collected in data-dependent mode, with the top five ions from each scan selected for higher-energy collisional dissociation (HCD) MS2 fragmentation analysis with a normalized collision energy of 25.0%. A resolution of 17,500 was used for both MS1 and MS2.

Stable isotope labeling studies. Isotopically labeled media were prepared by adding 1 mM (each) [13C6]anthranilate or L-tryptophan-D5 to plates of minimal medium containing glucose. The plates were inoculated with concentrated spore stocks of A. terreus and incubated at 30°C for 5 days. Metabolites were extracted from the plates using Oasis hydrophilic lipophilic balance solid phase extraction cartridges, with elution using 100% methanol. Extracts were dried in vacuo and analyzed by LC-MS as described above.

Sequence analysis of AtFAC7019. To compare the AtFAC7019 DNA sequence to that of the A. terreus reference strain NIH 2624, a barcoded Illumina next-generation sequencing library of AtFAC7019 was generated using a True-Seq kit and pooled for sequencing with other samples at the University of Wisconsin–Madison Biotechnology Center DNA Sequencing Facility. A >1,000× coverage of the AtFAC7019 DNA sequence was achieved. A single contig (114,911 bp, completed and finished FAC clone sequence) was obtained using the DNAStar next-generation sequence assembly program. The entire FAC sequence was confirmed by FAC end sequences, Pmel and NotI digestion, and contour-clamped homogenous-electric field gel electrophoresis. From this sequencing, we identified 35,769 kb of extra sequence toward the telomere in AtFAC7019 that was not present in the reference genome (NIH 2624).

Purification and structural analysis of terreazepine. AtFAC7019-transformed A. nidulans were grown on 576 plates and extracted as described, yielding 400 mg of dried extract. The crude extract
was subjected to normal-stage flash chromatography using a CombiFlash NextGen 300 system (Teledyne-iSCCO) and examined using UV absorbance at 254 and 280 nm. The extract was separated using a 12-gold column (Teledyne-iSCCO) at a flow rate of 30 ml/min with a 50-min hexane/CHCl3/methanol (MeOH) gradient. Of the 12 resulting simplified fractions, fraction 6 contained the highest concentration of the target metabolite and was subjected to reversed-phase separation using an Agilent 1200 HPLC and analyzed using OpenLAB CDS Chemstation software (version number 1.8.1, Agilent Technologies). Fraction 6 (56.9 mg) was separated on a Kinetix C18 semipreparative column (5 μm; 100 Å; 250 × 10.0 mm; Phenomenex) at a flow rate of 2.5 ml/min. Approximately 200 μl of a 10-mg/ml solution was injected per run, and subsequent fractions were pooled together for analysis. The 45-min run began at 20.80 CH3CN-H2O and was increased to 40.60 over 20 min. The gradient was increased to 100% CH3CN over the next 20 min and held at 100% for the remainder of the run. Terreazepine eluted from 16 to 17.5 min (1.5 mg, 90% purity). All solvents used for chromatographic separation were acquired through Sigma-Aldrich and were HPLC-grade. MS2 spectra for terreazepine are shown in Fig. S2.

Nuclear magnetic resonance (NMR) spectra for the target compound, including 1H, 13C, correlation spectroscopy (COSY), heteronuclear multiple bond correlation (HMBC), and heteronuclear single quantum correlation (HSQC) spectra, were obtained using a Bruker Avance III 500-MHz system equipped with a DCH CryoProbe at 298 K. NMR spectra from the natural compound match those of the synthesized compound (see "Total synthesis and stereochrmical analysis of terreazepine" below and Fig. S3). NMR spectra of the synthetic compound in DMSO-d6 are the most complete and were used for full structural characterization (Table S2 and Fig. S3A to S3G). 1H and 13C NMR spectra are also provided for the synthetic compound in methanol-d4 (Fig. S3H and S3I).

1H NMR (500 MHz, DMSO-d6) δ 3.02 (dd, J = 18.7, 2.6 Hz, 1H), 3.24 (dd, J = 18.7, 13.3 Hz, 1H), 4.99 (dd, J = 13.2, 7.4 Hz, 2.4, 1H), 6.38 (br s, 2H), 6.54 (t, J = 7.9 Hz, 1H), 6.69 (dd, J = 8.1 Hz, 1H), 7.17 (m, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.27 (t, J = 7.6 Hz, 1H), 7.58 (dd, J = 7.6 Hz, 1H), 7.61 (td, J = 7.2, 1.4 Hz, 1H), 7.76 (dd, J = 7.9, 1.7 Hz, 1H), 8.42 (d, J = 7.4 Hz, 1H), 10.38 (s, 1H). 13C NMR (125 MHz, DMSO-d6) δ 45.75, 46.14, 113.87, 114.59, 116.36, 122.23, 124.36, 128.47 (2C), 130.12, 132.13, 134.25, 137.72, 149.70, 168.63, 171.25, 197.76.

1H NMR (500 MHz, methanol-d4) δ 7.89 (dd, J = 7.9, 1.6 Hz, 1H), 7.62 (td, J = 7.8, 1.7 Hz, 1H), 5.75 (dd, J = 7.9, 1.5 Hz, 1H), 7.32 (td, J = 7.5, 1.1 Hz, 1H), 7.22 (dd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.18 (dd, J = 8.1, 1.1 Hz, 1H), 6.76 (dd, J = 8.2, 1.1 Hz, 1H), 6.66 (dd, J = 8.1, 7.2, 1.1 Hz, 1H), 5.18 (dd, J = 12.4, 3.5 Hz, 1H), 3.26 (dd, J = 18.8, 12.3 Hz, 1H), 3.19 (dd, J = 18.8, 3.5 Hz, 1H). 13C NMR (126 MHz, methanol-d4) δ 197.84, 171.93, 169.80, 149.11, 137.29, 134.12, 132.13, 130.11, 129.00, 127.83, 124.76, 122.14, 116.75, 115.87, 115.24, 46.50, 46.24.

The 1H NMR spectrum (Fig. S3C) enabled detection of two CH2 protons (δ 3.02 and 3.24), one CH proton (δ 4.99), two amide protons (δ 8.42 and 10.38), two NH protons (δ 6.38), and eight aromatic protons (δ 6.54–7.76). This is consistent with the proposed molecular formula of C17H15N3O3. The presence of eight proton signals in the aromatic region is consistent with the presence of two carbons, further supporting the proposed molecular formula. Three of the signals corresponded to carbonyls, including two amides and one ketone (δ 168.63, 171.25, and 197.76, respectively), one was a CH2 (δ 45.75), one was an N-CH (δ 46.14), and 12 were aromatic CH or quaternary signals (8 CHs and 4 quaternaries, δ 113.87–149.70). 2D experiments were used to correlate aromatic 1H and 13C bonds, as well as to determine the connectivity of the molecule.

The HSQC experiment enabled linkage of protons to their corresponding carbons (Fig. S3F), while the COSY and HMBC spectra helped to build connections through the molecule. Three distinct portions of the molecule are evident using COSY correlations linking protons H-4 through H-7, protons H-8 through H-12, and protons H-15 through H-18 (Fig. S3E). The remainder of the molecule could be pieced together using HMBC correlations (Fig. S3G). We determined that the site of cyclization was at position 1 due to the correlation between the amide proton at H-2 and the carbonyl carbon C-1.

Total synthesis and stereochrmical analysis of terreazepine. Detailed descriptions and schemes for the total synthesis of (R)- and (S)-terreazepines as well as methods for the determination of their stereochemical configuration are provided in Text S1 in the supplemental material.

Bioinformatics analysis. (i) Creation of gene cluster family networks. We downloaded a data set of 1,037 fungal genomes from GenBank and the Joint Genome Institute Genome Portal, excluding Saccharomycesca as this subphyllum contains a large number of genomes with very few gene clusters. Biosynthetic gene clusters were detected using the command-line version of antiSMASH 4 with default parameters (41). For creation of gene cluster families, we used an approach similar to those mentioned (42, 43). Protein domains were detected using the HHMRE suite hmmsearch, resulting in protein domain arrays for each gene cluster. For each pair of gene clusters, the median sequence identity of backbone enzyme domains and the Jaccard similarity of protein domain sets was calculated. These two similarity metrics were combined for a single similarity score:

\[ \text{similarity score} = \sqrt{(0.8 \times \text{sequence identity}) + (0.2 \times \text{Jaccard similarity})} \]
A final clustering step was performed using DBSCAN clustering with an epsilon value of 0.55 (corresponding to a similarity score of 0.45). This process thus resulted in a network of gene clusters, where subgraphs correspond to gene cluster families. All gene cluster family dendrograms (Fig. 3 and Fig. S6) were created using unweighted-pair group method using average linkages (UPGMA) clustering based on this same cluster similarity score.

(ii) Sequence alignments. All sequence alignments were performed using MUSCLE with default parameters in MEGA. For the data in Table S3, adenylation domain sequences from IDO-containing gene clusters were aligned together with known adenylation domain sequences from MIBiG. Putative substrate-binding residues were extracted using gramicidin S synthetase as a reference.

(iii) Phylogenetic analyses. A maximum likelihood phylogenetic tree was constructed using default parameters in MEGAX (44) to produce a tree containing IDOs in 15 Aspergillus species. The tree was constructed using 500 bootstrap iterations.

(iv) Determining IDO counts per genome. All Aspergillus genomes included in this study were analyzed using the HMMER suite tool hmmsearch, using the IDO Pfam model (PF01231) as a query model, a minimum subject sequence length of 350 residues, and a maximum E value of 1E−30.

Data availability. The AtFAC7O19 sequence is available through GenBank under accession number MT376588. Experimental details (Text S1) and other supporting data, including Fig. S1 to S6 (phylogenetic trees, structural elucidation data, stereochemical evaluation data, and expanded details of IDO-containing fungal gene clusters), and Tables S1 to S3 (genome sequence alignments and primers, NMR summary, adenylation domain specificity codes, and C and T domain alignments) are included in the supplemental material.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

TEXT S1, DOCX file, 0.1 MB.

FIG S1, PDF file, 0.4 MB.
FIG S2, PDF file, 0.1 MB.
FIG S3, PDF file, 0.9 MB.
FIG S4, PDF file, 0.3 MB.
FIG S5, PDF file, 0.1 MB.
FIG S6, PDF file, 0.7 MB.
TABLE S1, PDF file, 0.2 MB.
TABLE S2, PDF file, 0.1 MB.
TABLE S3, PDF file, 0.3 MB.

ACKNOWLEDGMENTS
We acknowledge K. Clevenger and P. Gao for their contributions to developing the FAC-metabolite scoring platform. R. Betori and J. Zhu from K. Scheidt’s group are also acknowledged for their assistance with supercritical fluid chromatography analysis.

This work was funded by the U.S. National Institutes of Health SBIR grant R44AT009158 to C.C.W., J.W.B., and N.L.K., grant R01AI065728 to N.P.K., grant F32GM132679 to L.K.C. Part of this work was performed by the Northwestern University ChemCore, which is funded by Cancer Center support grant P30CA060553 from the National Cancer Institute awarded to the Robert H. Lurie Comprehensive Cancer Center and the Chicago Biomedical Consortium with support from the Searle Funds at the Chicago Community Trust. This work made use of the IMSEC and Northwestern University, which has received support from the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS-1542205), the State of Illinois, and the International Institute for Nanotechnology (IIN).

M.S., M.N.I., R.Y., and C.C.W. are employees of Intact Genomics that sells bacterial artificial chromosome (BAC) and FAC libraries, in addition to genome discovery and DNA research services, BAC cloning, DNA end repairing, E. coli competent cells, and other DNA and protein research kits.

REFERENCES
1. Cragg GM, Newman DJ. 2013. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 1830:3670–3695. https://doi.org/10.1016/j.bbagen.2013.02.008.
2. Cragg GM, Pezzuto JM. 2016. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract 25:41–59. https://doi.org/10.1159/00043404.
3. Newman DJ, Cragg GM. 2016. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 79:629–661. https://doi.org/10.1021/acs.jnatprod.3b01055.
4. Roemer T, Xu D, Singh SB, Parish CA, Harris G, Wang H, Davies JE, Bills GF. 2011. Confronting the challenges of natural product-based antifungal discovery. Chem Biol 18:148–164. https://doi.org/10.1016/j.chembiol.2011.01.009.
42. Doroghazi JR, Albright JC, Goering AW, Ju KS, Haines RR, Tchalukov KA, Labeda DP, Kelleher NL, Metcalf WW. 2014. A roadmap for natural product discovery based on large-scale genomics and metabolomics. Nat Chem Biol 10:963–968. https://doi.org/10.1038/nchembio.1659.

43. Navarro-Munoz JC, Selem-Mojica N, Mullowney MW, Kautsar SA, Tryon JH, Parkinson EI, De Los Santos ELC, Yeong M, Cruz-Morales P, Abubucker S, Roeters A, Lokhorst W, Fernandez-Guerra A, Cappelini LTD, Goering AW, Thomson RJ, Metcalf WW, Kelleher NL, Barona-Gomez F, Medema MH. 2020. A computational framework to explore large-scale biosynthetic diversity. Nat Chem Biol 16:60–68. https://doi.org/10.1038/s41589-019-0400-9.

44. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. 2018. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. Mol Biol Evol 35:1547–1549. https://doi.org/10.1093/molbev/msy096.